OTCPK:IRCL.F

Stock Analysis Report

Executive Summary

InterCure Ltd. invests in the biomedical, life sciences, and biotechnology sectors in Israel and internationally.

Snowflake

Fundamentals

Adequate balance sheet and slightly overvalued.

Share Price & News

How has InterCure's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

21.7%

IRCL.F

-1.6%

US Medical Equipment

0.07%

US Market


1 Year Return

n/a

IRCL.F

13.8%

US Medical Equipment

8.9%

US Market

Return vs Industry: Insufficient data to determine how IRCL.F performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how IRCL.F performed against the US Market.


Shareholder returns

IRCL.FIndustryMarket
7 Day21.7%-1.6%0.07%
30 Day-26.3%-4.3%-0.3%
90 Day-23.1%-4.3%-1.6%
1 Yearn/a14.7%13.8%11.3%8.9%
3 Yearn/a70.7%65.6%46.3%36.8%
5 Yearn/a117.3%93.5%62.1%44.3%

Price Volatility Vs. Market

How volatile is InterCure's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is InterCure undervalued compared to its fair value and its price relative to the market?

22.05x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IRCL.F's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IRCL.F's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IRCL.F is good value based on its PE Ratio (22.1x) compared to the Medical Equipment industry average (41.8x).

PE vs Market: IRCL.F is poor value based on its PE Ratio (22.1x) compared to the US market (17.8x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IRCL.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IRCL.F is good value based on its PB Ratio (1.7x) compared to the US Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is InterCure forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as InterCure has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has InterCure performed over the past 5 years?

10.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: IRCL.F has become profitable over the past 5 years, growing earnings by 10.5% per year.

Accelerating Growth: IRCL.F has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: IRCL.F has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: IRCL.F's Return on Equity (6.6%) is considered low.


Return on Assets

ROA vs Industry: IRCL.F's Return on Assets is below or equal to the Medical Equipment industry average last year.


Return on Capital Employed

ROCE Improving: IRCL.F is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is InterCure's financial position?


Financial Position Analysis

Short Term Liabilities: IRCL.F's short term assets (₪60.2M) exceeds its short term liabilities (₪16.9M)

Long Term Liabilities: IRCL.F's short term assets (60.2M) exceeds its long term liabilities (652.0K)


Debt to Equity History and Analysis

Debt Level: IRCL.F's debt to equity ratio (5%) is considered satisfactory

Reducing Debt: IRCL.F's debt to equity ratio has reduced from 8.4% to 5% over the past 5 years.

Debt Coverage: IRCL.F's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if IRCL.F's interest payments on its debt are well covered by EBIT.


Balance Sheet

Inventory Level: IRCL.F has a low level of unsold assets or inventory.

Debt Coverage by Assets: IRCL.F's debt is covered by short term assets (assets are 4.352150x debt).


Next Steps

Dividend

What is InterCure's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate IRCL.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IRCL.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if IRCL.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IRCL.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IRCL.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of InterCure's salary, the management and board of directors tenure and is there insider trading?

5.8yrs

Average board tenure


CEO

Roei Zerahia 0

0yrs

Tenure

0

Roei Zerahia serves as the Chief Executive Officer at InterCure Ltd. (Canndoc Pharma). 


Board Age and Tenure

5.8yrs

Average Tenure

60yo

Average Age

Experienced Board: IRCL.F's board of directors are considered experienced (5.8 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Omri Batzir

    Corporate Controller

    • Tenure: 0yrs
  • Asher Zamir

    Chief Financial Officer

    • Tenure: 0yrs
    • Compensation: ₪49.00k
  • Roei Zerahia

    Chief Executive Officer

    • Tenure: 0yrs

Board Members

  • Jay Cohn (88yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Yoav Waizer (53yo)

    Director

    • Tenure: 7.8yrs
  • Shlomo Shalev (57yo)

    Director

    • Tenure: 0yrs
    • Compensation: ₪63.00k
  • Henry Black (83yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Giuseppe Mancia

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Michael Weber

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • David Salton (60yo)

    Independent Director

    • Tenure: 5.8yrs
    • Compensation: ₪11.00k
  • Joseph Izzo

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Ehud Grossman

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Ehud Barak

    Acting Chairman of the Board

    • Tenure: 1.1yrs

Company Information

InterCure Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: InterCure Ltd.
  • Ticker: IRCL.F
  • Exchange: OTCPK
  • Founded: 1994
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: ₪465.734m
  • Listing Market Cap: ₪131.880m
  • Shares outstanding: 106.92m
  • Website: https://www.intercure.com

Location

  • InterCure Ltd.
  • Ussishkin Street 11
  • Hadera
  • 3844346
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
INCRTASE (The Tel-Aviv Stock Exchange)YesOrdinary SharesILILSSep 2007
IRCL.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDSep 2007

Biography

InterCure Ltd. invests in the biomedical, life sciences, and biotechnology sectors in Israel and internationally. The company was formerly known as Ben Gavish Ltd. and changed its name to InterCure Ltd. in ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/23 00:49
End of Day Share Price2019/10/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.